HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M M Taketo Selected Research

Intestinal Polyposis (Polyposis, Intestinal)

9/2001Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.
2/2001Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
11/2000Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M M Taketo Research Topics

Disease

6Neoplasms (Cancer)
11/2017 - 02/2004
4Colonic Neoplasms (Colon Cancer)
11/2017 - 02/2001
4Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
01/2011 - 11/2000
4Polyps
05/2007 - 11/2000
3Carcinogenesis
01/2009 - 09/2001
3Intestinal Polyposis (Polyposis, Intestinal)
09/2001 - 11/2000
2Hyperplasia
01/2009 - 10/2000
1Adenocarcinoma
11/2017
1Carcinoma (Carcinomatosis)
03/2011
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2011
1Endometrial Neoplasms (Endometrial Cancer)
01/2009
1Metaplasia
01/2009
1Neoplasm Metastasis (Metastasis)
07/2007
1Stomach Neoplasms (Stomach Cancer)
05/2007
1Chromosomal Instability (Chromosome Stability)
05/2007
1Hamartoma
02/2004
1Intestinal Polyps
09/2001
1Adenoma (Adenomas)
09/2001
1Colonic Polyps
02/2001
1Confusion (Bewilderment)
10/2000
1Mitochondrial Diseases (Mitochondrial Disease)
04/2000

Drug/Important Bio-Agent (IBA)

3beta CateninIBA
01/2009 - 02/2001
2Proteins (Proteins, Gene)FDA Link
03/2011 - 02/2001
2Prostaglandins EIBA
02/2004 - 09/2001
2Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
02/2004 - 02/2001
1Sirolimus (Rapamycin)FDA Link
11/2017
1ErbB Receptors (EGF Receptor)IBA
11/2017
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2017
1(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA
11/2017
1trametinibIBA
11/2017
1EverolimusFDA Link
11/2017
1Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2017
1Mechanistic Target of Rapamycin Complex 1IBA
11/2017
1temsirolimusFDA Link
11/2017
1Codon (Codons)IBA
10/2017
1villinIBA
10/2017
1TamoxifenFDA LinkGeneric
10/2017
1CateninsIBA
01/2011
1Chemokine ReceptorsIBA
07/2007
1LigandsIBA
07/2007
1ChemokinesIBA
07/2007
1Indicators and Reagents (Reagents)IBA
05/2007
1TCF Transcription FactorsIBA
05/2007
1ProstaglandinsIBA
02/2004
1Transforming Growth Factor-beta Type II ReceptorIBA
10/2001
1Bromodeoxyuridine (BrdU)IBA
10/2001
1Transforming Growth Factor beta (TGF-beta)IBA
10/2001
1Estrogens (Estrogen)FDA Link
10/2001
1Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
10/2001
1Prostaglandin H2 (PGH(2))IBA
09/2001
1IsoenzymesIBA
09/2001
1Cell Surface ReceptorsIBA
09/2001
1Prostaglandin Receptors (Prostaglandin Receptor)IBA
09/2001
1Dinoprostone (PGE2)FDA Link
09/2001
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2001
1Transcription Factors (Transcription Factor)IBA
02/2001
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2001
1Sulindac (Copal)FDA LinkGeneric
02/2001
1rofecoxib (Vioxx)FDA Link
02/2001
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
02/2001
1Phospholipases (Phospholipase)IBA
11/2000
1Arachidonic Acid (Vitamin F)IBA
11/2000
1Secretory Phospholipases A2IBA
11/2000
1Messenger RNA (mRNA)IBA
11/2000
1Keratin-8 (Keratin 8)IBA
10/2000
1K-18 conjugate (K18)IBA
10/2000
1Caspase 3 (Caspase-3)IBA
04/2000

Therapy/Procedure

1Aftercare (After-Treatment)
10/2001
1Chemoprevention
02/2001